Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (<scp>CLL2‐BCG</scp>): Final analysis of a multicenter, open‐label <scp>phase‐II</scp>‐trial

Paula Cramer, Julia von Tresckow, Anna‐Maria Fink, Sandra Robrecht, Adam Giza, Eugen Tausch, Lothar Müller, Wolfgang Knauf, Matthias Zingerle, Othman Al‐Sawaf, Petra Langerbeins, Kirsten Fischer, Karl‐Anton Kreuzer, Michael Kneba, Clemens‐Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek

doi:HTTPS://DOI.ORG/https://doi.org/10.1002/ajh.27304

Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (<scp>CLL2‐BCG</scp>): Final analysis of a multicenter, open‐label <scp>phase‐II</scp>‐trial

Authors: Paula Cramer, Julia von Tresckow, Anna‐Maria Fink, Sandra Robrecht, Adam Giza, Eugen Tausch, Lothar Müller, Wolfgang Knauf, Matthias Zingerle, Othman Al‐Sawaf, Petra Langerbeins, Kirsten Fischer, Karl‐Anton Kreuzer, Michael Kneba, Clemens‐Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek

Published: 2024-04-05

DOI: HTTPS://DOI.ORG/https://doi.org/10.1002/ajh.27304

Keywords: No keywords found.

Abstract:
No abstract found.

Source: